<DOC>
	<DOCNO>NCT01050764</DOCNO>
	<brief_summary>When match relate match unrelated donor available Haploidentical donor ( parent , sibling child ) immediately available . The challenge associate haploidentical HCT include increase risk GVHD , graft rejection impair immune reconstitution . This trial evaluate safety feasibility simultaneous administration conventional T cell regulatory T cell haploidentical allogeneic hematopoietic cell transplantation overcome challenge .</brief_summary>
	<brief_title>Haploidentical Allogeneic Transplant w/Post Transplant Infusion Regulatory T-cells ( BMT Protocol 204 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Recipient Inclusion Criteria 3.1.1 Patients follow disease histopathologically confirm eligible : 1 . Acute leukemia ( first remission poor risk factor molecular prognosis ; AML 5,7 , ( 6 ; 9 ) , tri8 , 11 ALL Ph+ ( 9 ; 22 ) , ( 4 ; 22 ) , ( q34 ; q11 ) 2 . Acute leukemia refractory disease &gt; CR1 3 . Chronic myelogenous leukemia ( accelerate , blast second chronic phase ) 4 . Myelodysplastic syndrome ( high high intermediate risk category ) 5 . NonHodgkin 's lymphoma poor risk feature suitable autologous transplantation 6 . Refractory CLL 3.1.2 There limit amount prior therapy must least 21 day end recent prior therapy start transplant condition regimen . 3.1.3 The recipient must &lt; = 60 year old time registration . 3.1.5 Karnofsky Performance Status &gt; 70 % 3.1.6 The recipient must relate donor genotypically HLAA , B , C DRB1 , DQ loci haploidentical recipient ( differ 23 HLA allele unshared haplotype GvHD direction ) HLA match sibling match unrelated donor identify . 3.1.7 Adequate cardiac pulmonary function ( LVEF &gt; 45 % , DLCO &gt; 50 % correct hemoglobin ) 3.1.8 Serum creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 50 ml/min serum creatinine 1.5 ; serum bilirubin &lt; 2.0 mg/dL ; ALT &lt; 2x ULN ( unless secondary disease ) 3.1.9 No prior myeloablative therapy hematopoeitic cell transplantation Donor Inclusion Criteria 3.3.1 Age &lt; 70 year weight &gt; 25 kg . 3.3.2 Medical history physical examination confirm good health status define institutional standard 3.3.3 Seronegative HIV Ag , hepatitis B sAg PCR+ hepatitis C ab PCR+ within 30 day apheresis collection 3.3.4 Genotypically haploidentical determine HLA type 3.3.5 Female donor childbearing potential must negative serum urine betaHCG test within three week mobilization 3.3.6 Capable undergoing leukapheresis , adequate venous access , willing undergo insertion central catheter leukapheresis via peripheral vein inadequate 3.3.7 Capable agree second donation PBPC ( bone marrow harvest ) patient fail demonstrate sustain engraftment follow transplant 3.3.8 The donor legal guardian great 18 year age , capable signing IRBapproved consent form . 3.3.9 Donor Selection The order donor section follow : 1 . If available , recipient 's biological mother preferential donor 2 . If biological mother available , available haploidentical donor select base upon presence NK alloreactivity donor recipient . The donor select base presence NK alloreactivity determine highresolution HLA type C locus donor recipient . Recipients lack KIRligand present donor along correspond KIR define `` NK alloreactivity '' . An NK alloreactive donor preferentially choose . 3 . If 1 NK alloreactive donor available , preference use NK alloreactive donor CMV seronegative . Recipient Exclusion Criteria 3.2.1 The recipient suitable candidate autologous transplantation allogeneic transplantation available match relate unrelated donor . 3.2.2 Seropositive following : HIV ab , hepatitis B sAg PCR+ hepatitis C ab PCR+ 3.2.3 History invasive Aspergillosis ; presence active , uncontrolled bacterial , viral fungal infection 3.2.4 Uncontrolled CNS disease involvement 3.2.7 The recipient lactate female 3.4 Donor Exclusion Criteria 3.4.1 Evidence active infection viral hepatitis 3.4.3 Factors place donor increase risk complication leukapheresis GCSF therapy 3.4.4 Lactating female 3.4.5 HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>